Skip to main content

A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures

Journal of Neuro-Oncology volume 99, pages 251–260 (2010)Cite this article

Abstract

To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection. Brain tumor patients undergoing neurosurgery with ≥1 seizure within the preceding month prior to surgery were enrolled to receive intravenous levetiracetam for a minimum of 48 h, transitioned to oral levetiracetam at the same dose, and followed for 1-month after discharge. Patients were assessed daily in the hospital, provided with a seizure diary, and supplied with 30 days of levetiracetam upon discharge. Study patients were telephoned weekly to assess their cognitive status and seizure frequency. Of the 17 patients enrolled, the baseline seizure types were tonic clonic, partial, and complex partial with secondary generalization. The most common type of tumor was glioblastoma multiforme. Levetiracetam was well tolerated with no medication discontinuation during the study period. Adverse effects reported were somnolence, nausea/vomiting, headache, and insomnia. Eleven patients were evaluable for TICS scores (64.7%) with an average score of 33.3. Two patients were deemed to be cognitively impaired (18.2%). Eleven of twelve patients (91.7%) that completed the study period achieved a ≥50% reduction in their number of seizures. A total of 92 drug interactions were avoided (P = 0.0016) with dexamethasone, acetaminophen, and fentanyl being the most common. Levetiracetam monotherapy was found to be safe and tolerable in this patient population. Nearly all patients achieved a ≥50% reduction in seizure frequency post-op with levetiracetam monotherapy. Levetiracetam also has the potential for less drug interactions compared to phenytoin in these patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Central Brain Tumor Registry of the United States (2007–08) CBTRUS, Chicago

  2. Posner JB (1992) Management of brain metastases. Rev Neurol (Paris) 148:477–487

    CAS  Google Scholar 

  3. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31

    Article  CAS  PubMed  Google Scholar 

  4. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T (2001) Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-Oncology 3(3):152–158

    CAS  PubMed  Google Scholar 

  5. Villemure JG, de Tribolet N (1996) Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 9(6):424–428

    Article  CAS  PubMed  Google Scholar 

  6. Wen P (1997) The diagnosis and management of patients with brain tumors. In: Loeffler JS, Black PM (eds) Cancer of the nervous system. Blackwell Scientific, Boston, pp 106–127

    Google Scholar 

  7. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717–724

    CAS  PubMed  Google Scholar 

  8. Mamon HJ, Wen PY, Burns AC, Loeffler JS (1999) Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 40:341–344

    Article  CAS  PubMed  Google Scholar 

  9. Mahaley MS, Dudka L (1981) The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg Neurol 16:399–401

    Article  PubMed  Google Scholar 

  10. Hagen NA, Cirrincione C, Thaler HT et al (1990) The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 40:158–160

    CAS  PubMed  Google Scholar 

  11. Hung S, Hilsenbeck S, Feun L (1999) Seizure prophylaxis with phenytoin in patients with brain metastases. Proc Am Soc Clin Oncol 10:A1151

    Google Scholar 

  12. Moots PL, Maciunas RJ, Eisert DR et al (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717–724

    CAS  PubMed  Google Scholar 

  13. Glantz MJ, Cole BF, Friedberg MH et al (1996) A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46:985–991

    CAS  PubMed  Google Scholar 

  14. Forsyth PA, Weaver S, Fulton D et al (2003) Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 30(2):89–90

    Google Scholar 

  15. VanLandingham KE, Radtke RA (2002) Use of levetiracetam in patients with brain tumors and intractable partial epilepsy. Epilepsia 43(7):202

    Google Scholar 

  16. Siddiqui F, Wen P, Dworetzky B, Cabello D, Broomfield EB (2002) Use of levetiracetam in patients with brain tumors. Epilepsia 43(7):297

    Google Scholar 

  17. Penovich PE, Dickens DL, Gates JR et al (2004) Treating seizures due to brain neoplasms: rational new choices. Epilepsia 45(7):311

    Google Scholar 

  18. Larson SE, Sirven JI, Drazkowski JF, Zimmerman RS (2004) Efficacy and tolerability of levetiracetam in patients with brain tumors and seizures. Epilepsia 45(7):124

    Google Scholar 

  19. Stevens GHJ, Vogelbaum MA, Suh JH, Peereboom DM, Barnett GH (2005) Levetiracetam use in brain tumor patients. Neurology 64(1):A47–A48

    Google Scholar 

  20. Brandt J, Spencer M, Folstein M (1988) The telephone interview for cognitive status. Neuropsychiatr, Neuropsychol Behav Neurol 1(2):111–117

    Google Scholar 

  21. Ferrucci L, Del Lungo I, Guralnik JM et al (1998) Is the telephone interview for cognitive status a valid alternative in persons who cannot be evaluated by the mini mental state examination? Aging 10(4):332–338

    CAS  PubMed  Google Scholar 

  22. Naidech AM, Kreiter KT, Janjua N et al (2005) Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 36:583–587

    Article  CAS  PubMed  Google Scholar 

  23. Sanchez CE, Ogilvy CS, Carter BS (2007) Outcomes studies in cerebrovascular neurosurgery. Neurosurg Focus 22(3):1–21

    Article  Google Scholar 

  24. Valeriano JP, Lane CL (2005) Clinical experience with levetiracetam monotherapy in the treatment of epilepsy. Epilepsia 46(8):191

    Google Scholar 

  25. Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78(1):99–102

    Article  CAS  PubMed  Google Scholar 

  26. Newton HB, Dalton J, Goldlust S, Pearl D (2007) Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol 84(3):293–296

    Article  CAS  PubMed  Google Scholar 

  27. Rüegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P (2008) Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 12:477–480

    Article  PubMed  Google Scholar 

  28. Chang EF, Potts MB, Keles GE et al (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227–235

    Article  PubMed  Google Scholar 

  29. Milligan TA, Hurwitz S, Bromfield EB (2008) Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 71:665–669

    Article  CAS  PubMed  Google Scholar 

  30. Lim DA, Tarapore P, Chang E et al (2009) Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol 93(3):349–354

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research study was funded through a Young Investigator Research Grant provided by UCB Pharma.

Author information

Affiliations

  1. Department of Pharmacy, Methodist University Hospital, 1265 Union Ave, Memphis, TN, 38104, USA

    Justin B. Usery

  2. College of Pharmacy, University of Tennessee, Memphis, TN, USA

    Justin B. Usery & Christopher K. Finch

  3. Neurological Surgery, Methodist University Hospital, 1265 Union Avenue, Memphis, TN, 38104, USA

    L. Madison Michael II

  4. College of Medicine, University of Tennessee, Memphis, TN, USA

    L. Madison Michael II

  5. Department of Neurological Surgery, Vanderbilt Medical Center, T4224 Medical Center North, Nashville, TN, 37232-2380, USA

    Allen K. Sills

  6. College of Medicine, Vanderbilt University, Nashville, TN, USA

    Allen K. Sills

  7. Methodist University Hospital, 1265 Union Avenue, Memphis, TN, 38104, USA

    Christopher K. Finch

Authors
  1. Justin B. Usery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Madison Michael II
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allen K. Sills
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher K. Finch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Justin B. Usery.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Usery, J.B., Michael, L.M., Sills, A.K. et al. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 99, 251–260 (2010). https://doi.org/10.1007/s11060-010-0126-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0126-8

Keywords

  • Levetiracetam
  • Brain tumor
  • Seizures
  • Neurosurgery